Short communicationPublished 22 Feb 2021

Harnessing benefit from targeting tumour associated carbohydrate antigens

Authors: Thomas Kieber-Emmons University of Arkansas for Medical Sciences, USA

Journal of Cellular and Molecular Biology Research

Volume 2 · Issue 1 · Pages 7–8

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Integrating additive or synergistic antitumor effects that focus on distinct elements of tumor biology are the most rational of strategies for cancer treatment. The real challenge is to define what elements of tumor biology make the most sense to be targeted? Signal transduction (pathways) can define therapeutic strategies and approaches that might be tailored to harness benefit from sustained immunity much like that observed from natural antibodies involved in immune surveillance mechanisms. Tumor associated carbohydrate antigens (TACAs) are pan-targets on tumor cells because they play roles in initiation and metastases of cancer, and considered as common targets shared by many tumor types, and regulating a network of signaling pathways associated with cell survival. Strategies that target TACAs therefore have potential benefit as cell death therapies. We have been developing an active immunization strategy targeting TACAs using carbohydrate mimetic peptides (CMP) designed as panimmunogens

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. EuroSciCon does not store it.

Try:

More from this journal

The newest in Journal of Cellular and Molecular Biology Research.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cellular and Molecular Biology Research
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “USA”